Compare Global Payments Inc (GPN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Novartis AG — how do they compare? Global Payments Inc trades at $82.14 (market cap $21.46B), while Novartis AG trades at $143.12 (market cap $268.57B). The key difference: Novartis AG is far larger — about 12.5× Global Payments Inc's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and Novartis AG for 82 Days on average.
| GPN | NVS | |
|---|---|---|
Market Cap | $21.46B | $268.57B |
Volume | 1,482,600 | 1,532,573 |
Sector | Financials | Health |
52-Week High | $94.83 | $168.62 |
52-Week Low | $62.47 | $121.80 |
Typical Hold Time | 50 Days | 82 Days |
Enterprise Value | $39.60B | $309.89B |
Dividend Yield | 1.23% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $81.08, down 0.87% on the day, with a bearish technical signal and mixed fundamentals. The stock has beaten earnings estimates for the last three quarters, but 2026 projections show a net loss. Analyst consensus is bullish with a $102.75 price target, though rising debt and competition pose risks.
The outlook hinges on successful integration of Genius and Worldpay platforms to drive growth, but investor caution is warranted due to negative profit margins forecasted for 2026 and high debt levels. Near-term price action is testing key support at $80.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
